반응식
[CH2:1]([N:5]([CH2:15][CH2:16][CH2:17][CH3:18])[C:6]([C:8]1[C:12](Cl)=[C:11]([CH3:14])[NH:10][N:9]=1)=[O:7])[CH2:2][CH2:3][CH3:4].[O:19]1[CH2:24][CH2:23][CH2:22][CH2:21][CH:20]1[O:25][CH2:26]CC1NN=C(C(OCC)=O)C=1>>[CH2:1]([N:5]([CH2:15][CH2:16][CH2:17][CH3:18])[C:6]([C:8]1[CH:12]=[C:11]([CH2:14][CH2:26][O:25][CH:20]2[CH2:21][CH2:22][CH2:23][CH2:24][O:19]2)[NH:10][N:9]=1)=[O:7])[CH2:2][CH2:3][CH3:4]참가 물질
3
실험 절차
Following a procedure analogous to that for the synthesis of Intermediate 1B, ethyl 5-(2-(tetrahydro-2H-pyran-2-yloxy)ethyl)-1H-pyrazole-3-carboxylate (2.15 g, 8.01 mmol) was converted to the title compound (2.35 g, 83%). MS(ESI+) m/z 352.4 (M+H)+.
출처 및 근거
- ORD 기록
- ord-283cc6188a734fbb81716f84ca8a64f2
- 출처 데이터셋
- uspto-grants-2016_05
- 특허 번호
- US09346795B2
연결된 노트
불러오는 중…